Nonetheless, some studies do suggest that modulating TEX may influence RA disease outcome; immune checkpoint blockade reduces TEX and can result in onset of RA (55, 56) and a reduction of CD28- T cells (that may include TEX) has been associated with clinical response to abatacept (20). Here, CD28 is linked to rheumatoid arthritis.